Category: United States
-
Opposition brief filed: could copyright-related case law persuade Judge Albright to lift BMW’s antisuit injunction against Munich lawsuit over U.S. patents?
Onesta has raised various arguments against BMW’s antisuit motion, some of which are potentially more compelling than others.
-
Federal Circuit gives guidance on “connected to” not necessarily requiring separate structures; generic irreparable harm; DOE; admissible willfulness evidence
A precedential Federal Circuit decision in a child car seat case provided several clarifications, some of which address issues likely to resurface in other U.S. patent cases.
-
Judge Albright grants BMW antisuit TRO against Onesta with respect to Munich enforcement of U.S. patents: in force until December 30
BMW’s motion for a temporary restraining order was granted apart from a couple of items that clearly went beyond the reasonable scope of a TRO.
-
Solar panel patent wars continue to heat up in Germany, while CAT faces patent infringement suits in UPC, ITC, Eastern District of Texas
Solar panel manufacturer Maxeon has filed its third patent infringement lawsuit against Aiko Solar over solar technology patents in the Munich I Regional Court, while Caterpillar (CAT) has also been hit with a third suit over the alleged infringement of one of rival Doosan Bobcat’s hydraulic patents (following two in the U.S.).
-
BMW seeks U.S. antisuit and anti-anti-antisuit injunction against NPE Onesta’s Munich lawsuit over two U.S. patents: Western District of Texas
The first-ever assertion of U.S. patents in a German court has now drawn, anything but unexpectedly, countermeasures in U.S. district court.
-
Teva removes more than 200 patents from U.S. FDA’s Orange Book: win for FTC
Following President Trump’s promise to lower the cost of drugs and a United States Federal Trade Commission investigation into a patent portfolio owned by Teva, the Israeli pharma company has asked the Food and Drug Administration to remove more than 200 improper patent listings related to asthma, diabetes, and COPD drugs, and epinephrine autoinjectors, from…
-
U.S. appeals court to Apple: now prove the value of your IP in district court (for the first time since the Samsung patent spat)
An appellate ruling that largely upheld contempt sanctions imposed on Apple will now lead to further proceedings in district court.
-
Target sued in Eastern District of Texas over payment system patent infringement
Cardtek (PayCore) has sued U.S. retailer Target in the United States Districs Court for the Eastern District of Texas over the alleged infringement of three of its patents related to payment systems.
-
Some direct patent infringement “acceptable price” for expediting competition: U.S. Solicitor General urges Supreme Court to review skinny labeling and generic drug access
United States Solicitor General D. John Sauer has filed a petition urging the Supreme Court to intervene in a long-running drug patent infringement case in which he alleges the Federal Circuit failed to apply the “skinny labelling” (section viii) pathway, which allows the entry of generics that carve out patented uses but otherwise duplicate the…
-
USPTO Director Squires encourages fairer, more consistent patent eligibility in latest memoranda
USPTO Director John A. Squires reminds applicants and examiners that when used properly, Subject-Matter Eligibility Declarations can be effective, encouraging examiners not to reject patent applications too broadly.